Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 19Neoplasm Metastasis 9Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 3Colorectal Neoplasms 3Brain Neoplasms 3Recurrence 2Pancreatic Neoplasms 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Carcinoma, Renal Cell 2Advanced Cancer 2Unilateral Breast Neoplasms 1Thrombocytosis 1Solid Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

olaparib 1abemaciclib 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrent Ovarian High Grade Serous Adenocarcinoma × abemaciclib × Clear all
NCT04633239 2026-05-22

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
42 enrolled
Gynecologic

Recurrent Ovarian High Grade Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡